Variations in organism-specific severe sepsis mortality in the United States: 1999-2008

Critical Care Medicine

Volumn 43, Issue 1, 2015, Pages 65-77

  Ani, Chizobam ^a,b   Farshidpanah, Siavash ^b   Stewart, Amy Bellinghausen ^a   Nguyen, H Bryant ^a,b  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

Author keywords

National trend; Organism specific mortality; Severe sepsis

Indexed keywords

ADOLESCENT; ADULT; AGED; ANAEROBIC BACTERIUM; CHILD; COMORBIDITY; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; ICD-9-CM; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS; REVIEW; SEPSIS; SERRATIA; SEVERE SEPSIS; SPECIES DIFFERENCE; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS; EPIDEMIOLOGY; ESCHERICHIA COLI INFECTION; GRAM NEGATIVE INFECTION; HOSPITAL; INFANT; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS INFECTION; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; ESCHERICHIA COLI INFECTIONS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PSEUDOMONAS INFECTIONS; SEPSIS; STAPHYLOCOCCAL INFECTIONS; UNITED STATES; YOUNG ADULT;

EID: 84925683536     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000555     Document Type: Review

References (53)

1. Melamed A, Sorvillo FJ: The burden of sepsis-associated mortality in the United States from 1999 to 2005: An analysis of multiple-causeof-death data. Crit Care 2009; 13:R28
2. Elixhauser A, Friedman B, Stranges E: Septicemia in U.S. Hospitals, 2009: Statistical Brief #122. Rockville, MD, Agency for Health Care Policy and Research (US), 2011
3. Kochanek KD, Xu J, Murphy SL, et al: Deaths: Final Data for 2009: National Vital Statistics Reports. Hyattsville, MD, National Center for Health Statistics, 2012
4. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637
5. Levy MM, Dellinger RP, Townsend SR, et al; Surviving Sepsis Campaign: The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010; 38:367-374
6. Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med 2013; 369:840-851
7. Riedemann NC, Guo RF, Ward PA: The enigma of sepsis. J Clin Invest 2003; 112:460-467
8. Carson WFI, Kunkel SL: Molecular mechanisms underlying severe sepsis: Insights from epigenetics. In: Annual Update in Intensive Care and Emergency Medicine 2012. Vincent J-L (Ed). Berlin/Heidelberg, Springer, 2012, pp 3-11
9. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596
10. Dombrovskiy VY, Martin AA, Sunderram J, et al: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med 2007; 35:1244-1250
11. Kumar G, Kumar N, Taneja A, et al; Milwaukee Initiative in Critical Care Outcomes Research Group of Investigators: Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 2011; 140:1223-1231
12. Lagu T, Rothberg MB, Shieh MS, et al: Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012; 40:754-761
13. Lagu T, Rothberg MB, Shieh MS, et al: What is the best method for estimating the burden of severe sepsis in the United States? J Crit Care 2012; 27:414.e1-414.e9
14. Dombrovskiy VY, Martin AA, Sunderram J, et al: Facing the challenge: Decreasing case fatality rates in severe sepsis despite increasing hospitalizations. Crit Care Med 2005; 33:2555-2562
15. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
16. Stevenson EK, Rubenstein AR, Radin GT, et al: Two decades of mortality trends among patients with severe sepsis: A comparative metaanalysis. Crit Care Med 2014; 42:625-631
17. Zahar JR, Timsit JF, Garrouste-Orgeas M, et al: Outcomes in severe sepsis and patients with septic shock: Pathogen species and infection sites are not associated with mortality. Crit Care Med 2011; 39:1886-1895
18. Ahmed AJ, Kruse JA, Haupt MT, et al: Hemodynamic responses to gram-positive versus gram-negative sepsis in critically ill patients with and without circulatory shock. Crit Care Med 1991; 19:1520
19. Kinasewitz GT, Yan SB, Basson B, et al; PROWESS Sepsis Study Group: Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 2004; 8:R82-R90
20. Gao H, Evans TW, Finney SJ: Bench-to-bedside review: Sepsis, severe sepsis and septic shock-Does the nature of the infecting organism matter? Crit Care 2008; 12:213
21. Marshall J, Sweeney D: Microbial infection and the septic response in critical surgical illness. Sepsis, not infection, determines outcome. Arch Surg 1990; 125:17
22. Suffredini AF, Munford RS: Novel therapies for septic shock over the past 4 decades. JAMA 2011; 306:194-199
23. Marshall JC, Vincent JL, Fink MP, et al: Measures, markers, and mediators: Toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 2003; 31:1560-1567
24. Cohen J, Cristofaro P, Carlet J, et al: New method of classifying infections in critically ill patients. Crit Care Med 2004; 32:1510-1526
25. Rubulotta F, Marshall JC, Ramsay G, et al: Predisposition, insult/ infection, response, and organ dysfunction: A new model for staging severe sepsis. Crit Care Med 2009; 37:1329-1335
26. Cosgrove SE, Sakoulas G, Perencevich EN, et al: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36:53-59
27. Engemann JJ, Carmeli Y, Cosgrove SE, et al: Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36:592-598
28. Davis SL, Perri MB, Donabedian SM, et al: Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 2007; 45:1705-1711
29. Wang R, Braughton KR, Kretschmer D, et al: Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007; 13:1510-1514
30. Labandeira-Rey M, Couzon F, Boisset S, et al: Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315:1130-1133
31. Gasch O, Camoez M, Domínguez MA, et al; REIPI/GEIH Study Groups: Predictive factors for early mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2013; 68:1423-1430
32. Redondo MC, Arbo MD, Grindlinger J, et al: Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin Infect Dis 1995; 20:1492-1496
33. Goldstein EJ: Anaerobic bacteremia. Clin Infect Dis 1996; 23(Suppl 1):S97-101
34. Blairon L, De Gheldre Y, Delaere B, et al: A 62-month retrospective epidemiological survey of anaerobic bacteraemia in a university hospital. Clin Microbiol Infect 2006; 12:527-532
35. Micek ST, Welch EC, Khan J, et al: Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with Gram-negative bacteremia. J Hosp Med 2011; 6:405-410
36. Vincent JL, Sakr Y, Sprung CL, et al; Sepsis Occurrence in Acutely Ill Patients Investigators: Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006; 34:344-353
37. Micek ST, Welch EC, Khan J, et al: Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: A retrospective analysis. Antimicrob Agents Chemother 2010; 54:1742-1748
38. Osmon S, Ward S, Fraser VJ, et al: Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004; 125:607-616
39. Vidal F, Mensa J, Almela M, et al: Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156:2121-2126
40. Dellinger RP, Carlet JM, Masur H, et al; Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
41. Brun-Buisson C, Meshaka P, Pinton P, et al; EPISEPSIS Study Group: EPISEPSIS: A reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30:580-588
42. Vincent JL, Rello J, Marshall J, et al; EPIC II Group of Investigators: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-2329
43. Paul M, Shani V, Muchtar E, et al: Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54:4851-4863
44. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-1440
45. Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-1702
46. Panacek EA, Marshall JC, Albertson TE, et al; Monoclonal Anti-TNF: A Randomized Controlled Sepsis Study Investigators: Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182
47. Opal SM, Laterre PF, Francois B, et al; ACCESS Study Group: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. JAMA 2013; 309:1154-1162
48. Opal SM, Garber GE, LaRosa SP, et al: Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003; 37:50-58
49. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064
50. Styers D, Sheehan DJ, Hogan P, et al: Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5:2
51. Laupland KB: Incidence of bloodstream infection: A review of population-based studies. Clin Microbiol Infect 2013; 19:492-500
52. Walkey AJ, Wiener RS, Lindenauer PK: Utilization patterns and outcomes associated with central venous catheter in septic shock: A population-based study. Crit Care Med 2013; 41:1450-1457
53. Agency for Healthcare Research and Quality: Central venous catheter-related blood stream infection rate: Patient safety indicator #23. Version 4.5. Available at: http://qualityindicators.ahrq.gov/downloads/ modules/psi/v45/techspecs/psi%2023%20central%20venous%20 catheter-related%20blood%20stream%20infection%20rate.pdf. Accessed April 27, 2014